LINKER-AL2 shows linvoseltamab delivers rapid, deep responses in relapsed AL amyloidosis, addressing major unmet need with off-the-shelf access and a manageable safety profile.
Hans Lee, MD
Advertisement
Hans Lee, MD, is the director of myeloma research at Sarah Cannon Research Institute.
Articles by Hans Lee, MD
In part 2, Hans Lee, MD, shares practical tips for using linvoseltamab in heavily pretreated multiple myeloma and outlines trials that may expand its future role.
The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and de-escalation to monthly maintenance.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA
5